【レポートの概要(一部)】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 What Is This Report About? 11
3 Definitions of Markets/Categories Covered 12
3.1 In Vitro Diagnostics 12
3.1.1 Genetic Testing 12
3.1.2 Infectious Immunology 12
4 Company Snapshot 13
4.1 Key Facts 2011 13
4.2 Company Overview 13
4.3 Financial Performance 13
4.4 SWOT Snapshot 13
4.5 Business Overview 14
4.6 Major Products and Services 15
4.6.1 Overview 15
5 History 17
6 SWOT Analysis 19
6.1 Overview 19
6.2 Cepheid Strengths 19
6.2.1 Increasing Liquidity Ratios 19
6.2.2 The GeneXpert System 19
6.2.3 Strong In-house Research Expertise 20
6.2.4 Wide Market Applications 20
6.3 Cepheid Weaknesses 21
6.3.1 Termination of Supply Agreement with Roche 21
6.3.2 Product Recalls 21
6.3.3 Legal Proceedings 21
6.4 Cepheid Opportunities 22
6.4.1 Growth in Emerging Economies 22
6.4.2 Changing Demographics 22
6.4.3 New Product Launches and License Approvals 22
6.4.4 Inorganic Growth Strategies 22
6.5 Cepheid Threats 23
6.5.1 Cost Containment Pressures 23
6.5.2 Competitive Pressures 23
6.5.3 Government Regulations 23
6.5.4 Rapid Technological Advancements 23
7 Competitors 24
8 Competitive Landscape 25
8.1 In Vitro Diagnostics (Genetic Testing), Global, Market Share (%), 2011 25
8.2 Cepheid, In Vitro Diagnostics (Genetic Testing), by Region, Market Share (2011) 27
8.3 Cepheid, In Vitro Diagnostics (Genetic Testing), by Country, Market Share (2011) 28
8.4 In Vitro Diagnostics (Infectious Immunology), Global, Market Share (%), 2011 29
8.5 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Region, Market Share (2011) 31
8.6 Cepheid, In Vitro Diagnostics (Infectious Immunology), by Country, Market Share (2011) 32
9 Cepheid Medical Equipment Market Share Analysis by Category 33
9.1 Cepheid, In Vitro Diagnostics, Global, Category Revenue Share (2011) 33
9.2 Cepheid, North America, Category Revenue Share (2011) 35
9.2.1 Cepheid, United States, Category Revenue Share (2011) 37
10 Key Employees 39
11 Key Employee Biographies 40
12 Company Statement 41
13 Locations And Subsidiaries 42
13.1 Head Office 42
13.2 Other Locations & Subsidiaries 42
14 Financial Deals Landscape 43
14.1 Cepheid, Deals Volume Summary, 2007 to YTD 2013 43
15 Cepheid Detailed Deal Summary 45
15.1 Partnerships 45
15.1.1 Cepheid Enters Into Licensing Agreement With Quantovir 45
15.1.2 Cepheid Enters Into Co-Development Agreement With FIND 46
15.1.3 Cepheid Enters Into Collaboration With Novartis 47
15.1.4 Prodesse Enters Into Distribution Agreement With Cepheid 48
15.1.5 Cepheid Enters Into Agreement With Instrumentation Lab 49
15.1.6 Biomerieux Enters Into An Agreement With Cepheid 50
15.2 Acquisition 51
15.2.1 Cepheid Acquires Stretton Scientific 51
15.2.2 Nycomed Sells Its Interest In Sangtec Molecular Diagnostic To Cepheid 52
16 Recent Developments 54
16.1 Financial Announcements 54
16.1.1 Oct 18, 2012: Cepheid Reports Revenue Of $80.6m In Q3 2012 54
16.1.2 Jul 19, 2012: Cepheid Reports Revenue Of $81m In Q2 2012 54
16.1.3 Apr 19, 2012: Cepheid Reports Revenue Of $77.3m In Q1 2012 55
16.1.4 Jan 26, 2012: Cepheid Reports Revenue Of $277.6m In 2011 55
16.1.5 Oct 20, 2011: Cepheid Reports Total Revenues Of $70.2m In Q3 2011 56
16.1.6 Jul 21, 2011: Cepheid Reports Total Revenues Of $67m In Q2 2011 56
16.1.7 Apr 20, 2011: Cepheid Reports Total Revenues Of $60.2m In Q1 2011 57
16.1.8 Jan 27, 2011: Cepheid Reports Total Revenues Of $212.46 Million In 2010 57
16.1.9 Oct 21, 2010: Cepheid Reports Total Revenues Of $56.05 Million In Q3 2010 58
16.1.10 Jul 22, 2010: Cepheid Reports Total Revenues Of $49.64 Million In Q2 2010 58
16.1.11 Apr 22, 2010: Cepheid Reports Total Revenues Of $48 Million In Q1 2010 59
16.1.12 Jan 28, 2010: Cepheid Reports Total Revenues Of $170.6 Million In 2009 59
16.1.13 Oct 28, 2009: Cepheid Reports Revenues Of $41.6 Million In Q3 2009 59
16.1.14 Jul 30, 2009: Cepheid Reports Total Revenues Of $41.02 Million In Q2 2009 60
16.1.15 Apr 23, 2009: Cepheid Posts Net Loss Of $7.4 Million, Revenues Of $44.8 million For Q1 2009 61
16.1.16 Feb 05, 2009: Cepheid Reports 2008 Results 61
16.1.17 Jan 13, 2009: Cepheid Reports Preliminary 2008 Results 62
16.1.18 Jan 13, 2009: Cepheid To Declare Full Year 2008 Results 62
16.1.19 Oct 28, 2008: Cepheid Reports 3Q 2008 Results 62
16.1.20 Oct 28, 2008: Cepheid Reports Third Quarter Revenue Of $44.9 Million 63
16.1.21 Oct 03, 2008: Cepheid To Report 3Q 2008 Results 64
16.1.22 Jul 24, 2008: Cepheid Reports 2Q 2008 Results 64
16.1.23 Jul 24, 2008: Cepheid Reports Second Quarter Revenue Of $42.1 Million 65
16.1.24 May 01, 2008: Cepheid Reports Q1 2008 Results 66
16.1.25 May 01, 2008: Cepheid Reports Record Revenue Of $44.8 Million 67
16.1.26 Apr 07, 2008: Cepheid To Report Q1 2008 Results 69
16.1.27 Feb 28, 2008: Cepheid Reports Q4 2007 Results 69
16.1.28 Feb 28, 2008: Cepheid Reports Fourth Quarter And Full Year 2007 Results 71
16.1.29 Nov 01, 2007: Cepheid Reports Third Quarter 2007 Results 73
16.1.30 Nov 01, 2007: Cepheid Reports Q3 2007 Results 73
16.1.31 Aug 07, 2007: Cepheid Reports Q2 2007 Results 75
16.1.32 Aug 07, 2007: Cepheid Reports Second Quarter 2007 Results 76
16.1.33 May 03, 2007: Cepheid Reports Q1 2007 Results 77
16.1.34 May 03, 2007: Cepheid Reports First Quarter 2007 Results 78
16.1.35 Feb 22, 2007: Cepheid Reports Q4 2006 Results 80
16.1.36 Feb 22, 2007: Cepheid Reports Fourth Quarter And Full Year 2006 Results 82
16.1.37 Nov 02, 2006: Cepheid Reports Q3 2006 Results 83
16.1.38 Nov 02, 2006: Cepheid Reports Third Quarter 2006 Results 85
16.1.39 Aug 08, 2006: Cepheid Reports Second Quarter 2006 Results 86
16.1.40 May 04, 2006: Cepheid Reports First Quarter 2006 Results 88
16.1.41 Feb 22, 2006: Cepheid Reports Fourth Quarter 2005 Results 90
16.1.42 Nov 03, 2005: Cepheid Reports Third Quarter 2005 Results 92
16.1.43 Aug 04, 2005: Cepheid Reports Second Quarter 2005 Results 93
16.1.44 May 04, 2005: Cepheid Reports First Quarter 2005 Results 95
16.1.45 Feb 28, 2005: Cepheid Reports Fourth Quarter And Fiscal Year 2004 Results 97
16.1.46 Nov 02, 2004: Cepheid Reports Third Quarter And Nine Months 2004 Results 99
16.1.47 Aug 04, 2004: Cepheid Reports Second Quarter And Six Months 2004 Results 100
16.1.48 May 05, 2004: Cepheid Reports First Quarter 2004 Results 102
16.1.49 Feb 17, 2004: Cepheid Reports Fourth Quarter And Fiscal Year 2003 Results 104
16.1.50 Jan 29, 2004: Cepheid Reports Preliminary Financial Results For Fourth Quarter And Fiscal Year 2003 106
16.1.51 Nov 04, 2003: Cepheid Reports Third Quarter And Nine Months 2003 Results 106
16.1.52 Jul 31, 2003: Cepheid Reports Second Quarter And Six Months 2003 Financial Results 108
16.1.53 Apr 30, 2003: Cepheid Reports First Quarter 2003 Results 110
16.1.54 Feb 05, 2003: Cepheid Reports Fourth Quarter And Full Year 2002 Results 111
16.1.55 Nov 06, 2002: Cepheid Reports Third Quarter 2002 Results 113
16.1.56 Jul 15, 2002: Cepheid Reports Second Quarter 2002 Financial Results 114
16.1.57 Apr 23, 2002: Cepheid Reports First Quarter 2002 Results 116
16.1.58 Feb 05, 2002: Cepheid Reports Fourth Quarter 2001 Results. 117
16.1.59 Oct 23, 2001: Cepheid Reports Third Quarter 2001 Results 118
16.1.60 Jul 24, 2001: Cepheid Reports Second Quarter 2001 Results 119
16.1.61 Apr 23, 2001: Cepheid Reports First Quarter 2001 Results 120
16.1.62 Feb 07, 2001: Cepheid Reports Fourth Quarter And Year End 2000 Results 122
16.1.63 Oct 23, 2000: Cepheid Reports Third Quarter Results 123
16.1.64 Jul 25, 2000: Cepheid Reports Second Quarter Results Initial Sales Of Smart Cycler Launched In May 124
16.2 Corporate Communications 125
16.2.1 Jun 22, 2011: Cepheid Appoints Robert Kwiatkowski As Vice President Of Infectious Disease R&D 125
16.2.2 Feb 28, 2011: Cepheid Appoints Michael Bates As Vice President Of Oncology Research And Development 125
16.2.3 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As EVP, Worldwide Commercial Operation 126
16.2.4 Oct 13, 2009: Cepheid Appoints Nicolaas Arnold As Executive Vice President Of Worldwide Commercial Operations 126
16.2.5 Feb 11, 2008: Cepheid Appoints SVP And CFO 127
16.2.6 Feb 07, 2006: Cepheid Appoints New Board Member 127
16.3 Legal and Regulatory 128
16.3.1 Sep 26, 2012: Abaxis Announces Settlement Of Patent Litigation With Cepheid 128
16.3.2 Jul 13, 2010: Cepheid Files Answer And Counterclaims In Abaxis Patent Suit 128
16.4 Product News 128
16.4.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 128
16.4.2 Aug 15, 2012: CCMC Selects Cepheid’s GeneXpert System 129
16.4.3 Aug 06, 2012: Cepheid Announces First Phase Of Xpert MTB/RIF Buy-Down For High Burden Developing Countries 130
16.4.4 Jul 25, 2012: Cepheid Announces Release Of Updated Xpert BCR-ABL Monitor Test 130
16.4.5 Jun 14, 2012: Cepheid Welcomes UNITAID Commitment To Broaden Access To Xpert MTB/RIF 131
16.4.6 May 24, 2012: Cepheid Receives FDA Clearance For GeneXpert Infinity-80 System For Initial Use With Xpert Flu Assay 132
16.4.7 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 132
16.4.8 May 23, 2012: Cepheid Receives CE Mark For Xpert CT/NG 132
16.4.9 Aug 09, 2011: Cepheid Releases Updated Xpert BCR-ABL Monitor Test 133
16.4.10 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 133
16.4.11 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 133
16.4.12 Dec 27, 2010: Cepheid Announces European Release Of Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 134
16.4.13 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 134
16.4.14 Jul 01, 2010: Cepheid Issues Recall Of Xpert MRSA/SA BC Product 135
16.4.15 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 135
16.4.16 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 136
16.4.17 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 136
16.4.18 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 137
16.4.19 Jun 17, 2009: Cepheid Releases Improved Xpert BCR-ABL Monitor Test In Europe 138
16.4.20 Apr 27, 2009: Cepheid Launches Xpert MTB/RIF Molecular Test In Europe 138
16.4.21 Mar 31, 2009: Cepheid Launches Xpert MRSA/SA Nasal Test In Europe 139
16.4.22 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 139
16.4.23 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 139
16.4.24 Nov 10, 2008: Cepheid Launches First On-Demand Molecular Diagnostic Test For Clostridium Difficile Into European Market 140
16.4.25 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 140
16.4.26 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 141
16.4.27 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 141
16.4.28 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 141
16.4.29 Jul 29, 2008: Cepheid Introduces GeneXpert Infinity-48 System At 2008 American Association Of Clinical Chemistry Meeting 142
16.4.30 Jul 28, 2008: Cepheid GeneXpert System Selected For Upto 11 Victoria, Australia Hospitals In Rollout Of Start Clean Strategy 142
16.4.31 Jul 28, 2008: Cepheid Xpert MRSA Selected In Rollout Of Start Clean Strategy 143
16.4.32 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico EV Test Menu In Canada And Mexico 143
16.4.33 Jun 03, 2008: Cepheid (CPHD) Market Reach Extended With Licenses In Canada And Registrations In Mexico GBS Test Menu In Canada And Mexico 143
16.4.34 Apr 03, 2008: Cepheid Selected As Vendor Of Choice By Connecticut Hospital Association Shared Services Program For Molecular MRSA Surveillance Testing 144
16.4.35 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 144
16.4.36 Jan 07, 2008: Cepheid Begins Shipment Of Next Generation GeneXpert Molecular Diagnostic Systems 145
16.4.37 Dec 04, 2007: Cepheid Launches New GeneXpert Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus 146
16.5 Product Approvals 146
16.5.1 Dec 27, 2012: Cepheid Receives FDA Clearance For Xpert CT/NG 146
16.5.2 May 23, 2012: Cepheid Receives CE Mark For Xpert CT 147
16.5.3 Apr 26, 2011: Cepheid Receives FDA Clearance For Xpert Flu, Delivering Simultaneous Detection And Differentiation Of Flu A, Flu B and 2009 H1N1 Strain 147
16.5.4 Apr 11, 2011: Cepheid Receives FDA Approval For Xpert C. difficile/Epi Test 147
16.5.5 Jun 08, 2010: Cepheid Receives FDA Clearance For Xpert SA Nasal Complete Molecular Test For Simultaneous Detection And Differentiation Of S. aureus And MRSA Colonization 148
16.5.6 Jan 06, 2010: Cepheid Gains FDA Approval For Its Xpert vanA/vanB 148
16.5.7 Jan 04, 2010: Cepheid Gains Emergency Use Authorization From FDA For First 2009 H1N1 Influenza Assay For CLIA Moderate Complexity Laboratories 149
16.5.8 Jul 13, 2009: US FDA Grants Approval To Cepheid’s Xpert C. difficile Test 149
16.5.9 Mar 11, 2009: Cepheid’s Xpert MRSA/SA Blood Culture (BC) Test Receives Health Canada License 150
16.5.10 Nov 24, 2008: Cepheid Receives Health Canada License For First Molecular Diagnostic Test For MRSA And S. aureus Soft Tissue Infections 150
16.5.11 Nov 04, 2008: Cepheid Molecular Diagnostic Test For Positive Blood Culture Bottles Categorized ‘Moderate Complexity’ By FDA 151
16.5.12 Oct 07, 2008: Cepheid (CPHD) Announces CE IVD Release Of First On-Demand Test For van A/van B Genes 151
16.5.13 Oct 01, 2008: Cepheid Receives FDA Clearance For First On-Demand Diagnostic Test For Life-Threatening MRSA And Staphylococcus Aureus 151
16.5.14 Sep 29, 2008: Cepheid Receives FDA Clearance For First Rapid On-Demand Molecular Diagnostic Test For MRSA And S. Aureus 152
16.5.15 Jan 29, 2008: Cepheid Receives Health Canada Medical Device License For Xpert MRSA Test And GeneXpert System 152
16.6 Clinical Trials 153
16.6.1 Sep 02, 2010: New England Journal Of Medicine Study Reports Cepheid’s Xpert MTB/RIF Faster, More Sensitive And Specific Test For Tuberculosis 153
16.7 Other Significant Developments 153
16.7.1 Jun 29, 2011: ‘Art Meets Innovation’ Event Teams Cepheid With Paul Jr Designs For Unveiling of New Products At 2011 AACC/ASCLS Meeting 153
16.7.2 May 18, 2011: Cepheid Signs Distribution Agreement With LABSCO In US 154
17 Appendix 155
17.1 Research Methodology 156
17.2 Secondary Research 156
17.3 Primary Research 156
17.4 Models 157
17.5 Forecasts 157
17.6 Expert Panels 157
17.7 GlobalData Consulting 157
17.8 Currency Conversion 158
17.9 Contact Us 159
17.10 Disclaimer 159
【レポート販売概要】
■ タイトル:Cepheid:市場シェア分析■ 英文:Cepheid Market Share Analysis
■ 発行日:2013年2月15日
■ 調査会社:GlobalData
■ 商品コード:GDATA403160379
■ 調査対象地域:グローバル
- 抗菌コーティングの世界市場分析:製品別(抗菌パウダーコーティング(銀、銅)、表面改質剤およびコーティング(大腸菌、リステリア、シュードモナス)、用途別(プラスチック、塗料・コーティング、パルプ・紙)、用途別、動向・動態、競争戦略と予測、2014-2025The global antimicrobial coatings market is expected to reach USD 8.43 billion by 2025, according to a new report by Grand View Research, Inc. Increasing concern among professional industry manufactures about cleaning and to prevent buildings against the growth of bacteria, mold and fungi are expected to drive the overall market growth. Recent food poisoning outbreaks coupled with high rates of ho …
- 世界の無機塩基市場2015The Global Inorganic Bases Industry Report 2015 is a professional and in-depth study on the current state of the Inorganic Bases industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Inorganic Bases market analysis is provided for the international markets including development trends, competitive landsc …
- General Anxiety Disorder:グローバル臨床試験レビューH2, 2013General Anxiety Disorder Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “General Anxiety Disorder Global Clinical Trials Review, H2, 2013" provides data on the General Anxiety Disorder clinical trial scenario. This report provides elemental information and data relating to the clinical trials on General Anxiety Disorder. It includes an overview of the trial num …
- 超低温フリーザーの世界市場2017-2021ABSTRACTAbout Ultra-Low Temperature Freezer The global ULT freezers market is growing moderately at a rate of 3.08%, which can be attributed to increased investments in R&D. Also, the market is driven by the expansion of end-user segments such as biobanks, hospitals and diagnostic centers, and others that use cold storage solutions such as ULT freezers to store a broad range of specimens and produ …
- 世界のミクロスフェア(Microsphere)市場Rising demand for efficiency and better materials with superior structural properties will drive the global microspheres market to $5.2 billion by 2018. U.S. leads the world in terms of usage of advanced materials to increase the efficiency and reliability of operations which makes it the biggest market for microspheres. The market here is expected to experience highest revenue growth during the n …
- 建設用接着剤の世界市場:アクリル接着剤、ポリウレタン接着剤、酢酸ビニル樹脂接着剤、エポキシ接着剤The construction adhesive market is estimated to reach around $10.56 Billion by value by 2020, signifying a firm CAGR of around 5.13% between 2015 and 2020. The global construction adhesive market, along with its applications, showed a moderate growth in the past few years and is estimated to continue in the coming years. An increase in the demand in ceramic tile, concrete, pipe cements, counterto …
- スマートシリンジポンプの世界市場2019-2023About this market The growing number of surgical procedures and technological advances will foster market growth during the forecast period. Due to the rising incidence of several diseases, the number of surgical procedures performed annually has increased over the last decade. Smart syringe pumps are used as an important therapeutic tool to deliver medications continuously during critical care an …
- 手術用開創器の世界市場予測(~2023年)“The surgical retractors market is projected to grow at a CAGR of XX% during the forecast period”The global surgical retractors market is projected to reach USD 2.5 billion by 2023 from USD 1.8 billion in 2018, at a CAGR of 7.2%. The growth of this market is largely driven by factors such as the increasing number of surgical procedures; growing availability of specialized and application specific …
- 世界の食品安全性検査・診断市場予測:サルモネラ菌、リステリア菌、大腸菌、GMO、毒素、農薬検査などThe world market for the Food Safety Testing & Diagnostics will reach $11.03bn in 2014. Quality and safety testing of food is an area of growing importance, where accurate analytical results are critical, be that for exporters, importers or government bodies. With rising globalisation levels, standardisation of food safety testing methods across the world becomes paramount to all food industry pla …
- 影響分析:中国の食品安全検査市場および法規制The food safety testing market is projected to grow at a CAGR of 9.9% from 2015, to reach USD 791.5 Million by 2020. The market growth is driven by changing consumers’ attitude and concerns of retailers for safe and quality food, positive structural changes in the Chinese food safety regulations, high occurrence of food safety incidents in China, and globalization of food trade and China’s rising …
- 世界の海洋支援船(OSV)市場:アンカーハンドリング・タグサプライ船、プラットフォーム・サプライ船、緊急支援・坑井改修船、多目的補給船などAbout OSV OSV is a sea motor vessel used for transmitting cargos, goods, supplies, crews, and offshore exploration and production equipment across oil platforms. OSV supports marine offshore drilling activities through the transportation of offshore energy resources, and it also facilitates oil rigs installation process. It is mostly used by oil and gas companies for exploration and production (E& …
- 睡眠時無呼吸症候群向け口腔内装置の世界市場:製品別(下顎前方移動装置、舌前方保持装置)、タイプ別(医師処方・オーダーメイド、オンラインOTC)、地域別予測Global Sleep Apnea Oral Appliances Market to reach USD 700.8 million by 2025. Global Sleep Apnea Oral Appliances Market valued approximately USD 303.6 million in 2016 is anticipated to grow with a healthy growth rate of more than 9.74% over the forecast period 2017-2025. Growth in this market is mainly driven by the factor of growing popularity of oral appliances amongst population with sleep apne …
- 非増殖性糖尿病性網膜症(NPDR):グローバル臨床試験動向(2014年上半期)Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Global Clinical Trials Review, H1, 2014" provides data on the Non-Proliferative Diabetic Retinopathy (NPDR) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non …
- 世界の画像診断(医療機器)市場動向及び予測(~2018)The global diagnostic imaging market is estimated to grow at a CAGR of 4.7% and is expected to reach ~$27,115.4 million by 2018. Although the mature markets hold larger shares in diagnostic imaging, the Asia-Pacific region is expected to grow at the highest CAGR of 5.9%. The growth of the diagnostic imaging market is primarily triggered by factors such as the rapidly increasing aging population, i …
- 世界のバイオ肥料市場The global biofertilizers market consists of nitrogen fixing biofertilizers, phosphate solubilizing biofertilizers, potash mobilizing biofertilizers and other biofertilizers like Zinc and Sulphur solubilizing biofertilizers. Nitrogen fixing biofertilizers are the dominant sector of this market in terms of market revenue. The global biofertilizers market is dominated by Europe and Latin American co …